8-K: Xtant Medical Reports 28% Revenue Growth for Full Year 2024, Expects Continued Growth in 2025

Xtant Medical announces a 28% increase in revenue for 2024 and projects further growth in 2025, aiming for free cash flow generation in the second half of the year.

Summary

• Xtant Medical Holdings, Inc. reported its financial results for the fourth quarter and full year ended December 31, 2024.
• Full year 2024 revenue reached $117.3 million, a 28% increase compared to the previous year.
• The company expects revenue between $126 million and $130 million for 2025.
• Xtant Medical anticipates generating free cash flow in the second half of 2025.
• Fourth quarter revenue grew by 12% to $31.5 million compared to the same period in 2023.
• The company's gross margin for the fourth quarter was 50.8%, while the full year gross margin was 58.2%.
• The net loss for 2024 was $16.4 million, compared to a net income of $660,000 in 2023, which included a $11.7 million bargain purchase gain.
• Adjusted EBITDA for the full year 2024 was a loss of $2.3 million, compared to a loss of $1.4 million in the prior year.
• Operating expenses for the fourth quarter of 2024 totaled $17.9 million, compared to $20.9 million for the fourth quarter of 2023.
• As of December 31, 2024, the company had $6.2 million in cash and cash equivalents.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the strong revenue growth and positive outlook for 2025, but tempered by the net loss and negative EBITDA for the year.

Positives

• The company achieved a significant revenue growth of 28% for the full year 2024.
• Xtant Medical is projecting continued revenue growth in 2025, with guidance between $126 million and $130 million.
• The company expects to generate free cash flow in the second half of 2025.
• Operating expenses have been reduced by more than $5 million on an annualized basis.
• A new agreement provides an upfront payment of $1.5 million and minimum purchase obligations.

Negatives

• The company reported a net loss of $16.4 million for the full year 2024.
• The adjusted EBITDA for the full year 2024 was a loss of $2.3 million.
• Gross margin decreased to 58.2% for the full year 2024, compared to 60.8% in the prior year.
• Gross margin for the fourth quarter of 2024 was 50.8%, compared to 61.0% for the same period in 2023.

Risks

• The company's future operating results and financial performance could impact revenue.
• The company's ability to become operationally self-sustaining and less reliant on third-party manufacturers and suppliers could impact revenue.
• Risks associated with acquisitions and the integration of those businesses could impact revenue.
• Anticipated shortages of stem cells will adversely affect future revenues.
• The ability to implement successfully its future growth initiatives and risks associated therewith could impact revenue.
• Possible future impairment charges to long-lived assets and goodwill and write-downs of excess inventory could impact revenue.
• The ability to remain competitive could impact revenue.
• The ability to innovate, develop and introduce new products and the success of those products could impact revenue.
• The ability to engage and retain new and existing independent distributors and agents and qualified personnel and the Company's dependence on key independent agents for a significant portion of its revenue could impact revenue.
• The effect of labor and hospital staffing shortages on the Company's business, operating results and financial condition, especially when they affect key markets could impact revenue.
• The effect of inflation, increased interest rates and other recessionary factors and supply chain disruptions could impact revenue.
• The effect of product sales mix changes on the Company's financial results could impact revenue.
• Government and third-party coverage and reimbursement for Company products could impact revenue.
• The ability to obtain and maintain regulatory approvals and comply with government regulations could impact revenue.
• The effect of product liability claims and other litigation to which the Company may be subject could impact revenue.
• The effect of product recalls and defects could impact revenue.
• The ability to license certain of the Company's intellectual property on commercially reasonable terms and to maintain any such licenses could impact revenue.
• The ability to obtain and protect Company intellectual property and proprietary rights and operate without infringing the rights of others could impact revenue.
• Risks associated with the Company's clinical trials could impact revenue.
• International risks could impact revenue.
• The ability to service Company debt, comply with its debt covenants and access additional indebtedness could impact revenue.
• The ability to maintain sufficient liquidity to fund its operations and obtain financing on favorable terms or at all could impact revenue.

Future Outlook

Xtant Medical anticipates revenue between $126 million and $130 million for 2025 and expects to begin generating free cash flow in the second half of the year, enabling the company to support its expected organic growth without the need for additional external capital.

Management Comments

• Sean Browne, President and CEO of Xtant Medical, stated, 2024 was a year of significant accomplishments.
• Browne continued, The work we completed in 2024 to streamline our product portfolio and increase reliance on our own supply chain has enhanced product quality, reduced costs and, importantly, strengthened our business for sustainable, profitable growth.
• Brown concluded, Today, we are providing full year 2025 revenue guidance of $126 million to $130 million.

Industry Context

Xtant Medical's focus on orthobiologics and spinal implant systems positions it within a growing market driven by an aging population and increasing demand for minimally invasive surgical procedures. The company's efforts to streamline its product portfolio and enhance its supply chain align with industry trends focused on efficiency and cost reduction.

Comparison to Industry Standards

• Comparing Xtant Medical's 28% revenue growth in 2024 to competitors like Medtronic or Stryker, which typically see single-digit growth, suggests a strong performance, potentially driven by the Surgalign acquisition.
• However, the negative EBITDA contrasts with larger, more established players who generally report positive EBITDA margins.
• Companies like Globus Medical, which also focus on spinal implants, may serve as a benchmark for future profitability improvements at Xtant Medical.

Stakeholder Impact

• Shareholders may react positively to the revenue growth and future guidance.
• Employees may be affected by the cost reduction initiatives.
• Customers may benefit from the enhanced product quality and streamlined product portfolio.
• Suppliers may be impacted by the company's efforts to increase reliance on its own supply chain.

Next Steps

• The company will host a webcast and conference call on March 6, 2025, to discuss the financial results.
• Xtant Medical will file its Annual Report on Form 10-K for the year ended December 31, 2024, with the SEC on March 6, 2025.

Key Dates